NASDAQ:NVAX - Novavax Stock Price, Forecast & News

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVAX shares have increased by 33.5% and is now trading at $14.03. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Wednesday, March, 11th. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.06) by $0.07. The biopharmaceutical company earned $8.82 million during the quarter, compared to the consensus estimate of $3.99 million. View Novavax's earnings history.

Novavax's stock reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

7 Wall Street analysts have issued twelve-month price objectives for Novavax's shares. Their forecasts range from $7.00 to $24.00. On average, they anticipate Novavax's stock price to reach $18.86 in the next twelve months. This suggests a possible upside of 34.4% from the stock's current price. View analysts' price targets for Novavax.

Headlines about NVAX stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novavax earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutNovavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Gilead Sciences (GILD), Trevena (TRVN), Opko Health (OPK) and Inovio Pharmaceuticals (INO).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $14.03.

Novavax has a market capitalization of $722.97 million and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe. View additional information about Novavax.

The official website for Novavax is http://www.novavax.com/.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]